CD10 expression in urothelial carcinoma of the bladder

Diagnostic Pathology

Volumn 4, Issue 1, 2009, Pages

  Bahadir, Burak ^a   Behzatoglu, Kemal ^b   Bektas, Sibel ^a   Bozkurt, Erol R ^b   Ozdamar, Sukru O ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b Istanbul Education and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73249139730     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-4-38     Document Type: Article

References (72)

1. Global Cancer Statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
2. The biology and treatment of superficial bladder cancer. FM Torti BL Lum, J Clin Oncol 1984 2 505 31 6427417
3. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. JA Witjes CT Caris NA Mungan FM Debruyne WP Witjes, J Urol 1998 160 1668 1671 discussion 1671-1672 10.1016/S0022-5347(01)62377-2 9783928
4. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. H Huland U Otto M Droese G Klöppel, J Urol 1984 132 27 29 6427483
5. Selective bladder preservation by combination treatment of invasive bladder cancer. DS Kaufman WU Shipley PP Griffin NM Heney AF Althausen JT Efird, N Engl J Med 1993 329 1377 1382 10.1056/NEJM199311043291903 8413433
6. Evaluation and management of patients with superficial bladder cancer. MS Soloway, Urol Clin North Am 1987 14 771 780 3314068
7. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. S Holmäng H Hedelin C Anderström SL Johansson, J Uro 1995 153 1823 1826 discussion 1826-1827 10.1016/S0022-5347(01)67321-X
8. The common acute lymphoblastic leukemia antigen (CD10)-emancipation from a functional enigma. TW LeBien RT McCormack, Blood 1989 73 625 635 2465037
9. Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key! MA Shipp AT Look, Blood 1993 82 1052 1070 8102558
10. CD10: a review. DA Arber LM Weiss, Appl Immunohistochem Mol Morphol 1997 5 125 140 10.1097/00022744-199709000-00001 (Pubitemid 27461421)
11. Candidate leukaemia-specific antigen in man. G Brown N Hogg M Greaves, Nature 1975 258 454 456 10.1038/258454a0 1059878
12. Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues. RS Metzgar MJ Borowitz NH Jones BL Dowell, J Exp Med 1981 154 1249 1254 10.1084/jem.154.4.1249 6945392
13. Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens. JL Platt TW LeBien AF Michael, J Exp Med 1983 157 155 172 10.1084/jem.157.1.155 6600266
14. Granulocytes and cultured human fibroblasts express common acute lymphoblastic leukemia-associated antigens. MP Braun PJ Martin JA Ledbetter JA Hansen, Blood 1983 61 718 725 6572534
15. Localisation of CD10 to biliary canaliculi by immunoelectron microscopical examination. SL Loke CY Leung KY Chiu WL Yau KN Cheung L Ma, J Clin Pathol 1990 43 654 656 10.1136/jcp.43.8.654 2144860
16. Identification of myoepithelial cells in human and rat breasts byanti-common acute lymphoblastic leukemia antigen antibody A 12. BA Gusterson P Monaghan R Mahendran J Ellis MJ O'Hare, Natl Cancer Inst 1986 77 343 349
17. Differential localization within human kidney of five membrane proteins expressed on acute lymphoblastic leukemia cells. EJ Quackenbush A Gougos R Baumal M Letarte, J Immunol 1986 136 118 124 2415610
18. CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. ME Sunday J Hua JS Torday B Reyes MA Shipp, J Clin Invest 1992 90 2517 2525 10.1172/JCI116145 1469102
19. Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). P Hokland P Rosenthal JD Griffin LM Nadler J Daley M Hokland SF Schlossman J Ritz, J Exp Med 1983 157 114 129 10.1084/jem.157.1.114 6571733
20. Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. MF Greaves G Hariri RA Newman DR Sutherland MA Ritter J Ritz, Blood 1983 61 628 639 6338969
21. S Swerdlow E Campo NL Harris ES Jaffe SA Pileri H Stein J Thiele JW Vardiman, WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues Lyon: IARC 2008
22. Germinal centres in T-cell-dependent antibody responses. YJ Liu GD Johnson J Gordon IC MacLennan, Immunol Today 1992 13 17 21 10.1016/0167-5699(92) 90199-H 1739427
23. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. P Chu DA Arber, J Clin Pathol 2000 113 374 382 10.1309/8VAV-J2FU-8CU9-EK18
24. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. PG Chu DA Arber LM Weiss KL Chang, Mod Pathol 2001 14 465 471 10.1038/modpathol. 3880335 11353058
25. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. WG McCluggage VP Sumathi P Maxwell, Histopathology 2001 39 273 278 10.1046/j.1365-2559.2001. 01215.x 11532038
26. CD10 is a marker for normal and neoplastic endometrial stromal cells. T Toki M Shimizu Y Takagi T Ashida I Konishi, Int J Gynecol Pathol 2002 21 41 47 10.1097/00004347-200201000-00008 11781522
27. Solidpseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10. K Notohara S Hamazaki C Tsukayama S Nakamoto K Kawabata K Mizobuchi K Sakamoto S Okada, Am J Surg Pathol 2000 24 1361 1371 10.1097/00000478-200010000-00005 11023097
28. The pattern of CD10 expression in selected pathologic entities of the prostate gland. S Tawfic GA Niehans JC Manivel, Hum Pathol 2003 34 450 456 10.1016/S0046-8177(03)00077-7 12792918
29. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. J Kanitakis D Narvaez A Claudy, Melanoma Res 2002 12 241 244 10.1097/00008390-200206000-00007 12140380
30. Expression of CALLA/CD10 on human melanoma cells. S Carrel L Zografos M Schreyer D Rimoldi, Melanoma Res 1993 3 319 323 8292887 (Pubitemid 23329693)
31. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. N Bilalovic B Sandstad R Golouh JM Nesland I Selak EE Torlakovic, Modern Pathology 2004 17 1251 1258 10.1038/modpathol. 3800174 15205682
32. Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon. Y Sato F Itoh Y Hinoda Y Ohe N Nakagawa R Ueda A Yachi K Imai, J Gastroenterol 1996 31 12 17 10.1007/BF01211181 8808423
33. NCL-CD10-270: a new monoclonal antibody recognizing CD10 in parafin-embedded tissue. GG McIntosh AJ Lodge P Watson AG Hall K Wood JJ Anderson B Angus CH Horne ID Milton, Am J Pathol 1999 154 77 82 9916921
34. Downregulation of enkephalin-mediated inflammatory responses by CD10/neutral endopeptidase 24.11. MA Shipp GB Stefano L D'Adamio SN Switzer FD Howard J Sinisterra B Scharrer EL Reinherz, Nature 1990 347 394 396 10.1038/347394a0 1699130
35. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts. G Cutrona M Ulivi F Fais S Roncella M Ferrarini, J Exp Med 1995 181 699 711 10.1084/jem.181.2.699 7836923
36. Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. G Cutrona N Leanza M Ulivi G Melioli VL Burgio G Mazzarello G Gabutti S Roncella M Ferrarini, Blood 1999 94 3067 3076 10556191
37. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. F Morabito M Mangiola D Rapezzi S Zupo BM Oliva AM Ferraris M Spriano E Rossi C Stelitano V Callea G Cutrona M Ferrarini, Haematologica 2003 88 864 873 12935974
38. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. M Sumitomo R Shen M Walburg J Dai Y Geng D Navarro G Boileau CN Papandreou FG Giancotti B Knudsen DM Nanus, J Clin Invest 2000 106 1399 1407 10.1172/JCI10536 11104793
39. Cytokines increase neutral endopeptidase activity in lung fibroblasts. A Kondepudi A Johnson, Am J Respir Cell Mol Biol 1993 8 43 49 8380249
40. Cytokines and glucocorticoids modulate human bronchial epithelial cell peptidases. VH van der Velden BA Naber P van der Spoel HC Hoogsteden MA Versnel, Cytokine 1998 10 55 65 10.1006/cyto.1997.0257 9505146
41. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. CN Papandreou B Usmani Y Geng T Bogenrieder R Freeman S Wilk CL Finstad VE Reuter CT Powell D Scheinberg C Magill HI Scher AP Albino DM Nanus, Nat Med 1998 4 50 57 10.1038/nm0198-050 9427606
42. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. K Iwaya H Ogawa M Izumi M Kuroda K Mukai, Virchows Arch 2002 440 589 593 10.1007/s00428-002-0639-4 12070597
43. A new tumor marker for bladder cancer. K Koiso H Akaza M Ohtani N Miyanaga K Aoyagi, Int J Urol 1994 1 33 36 10.1111/j.1442-2042.1994.tb00005.x 7627835
44. CD10 mmunohistochemical staining in urothelial neoplasms. R Murali W Delprado, Am J Clin Pathol 2005 124 371 379 10.1309/04BHF6A80BQMH7HT 16191505
45. CD10 expression in urothelial bladder carcinomas: A pilot study. S Bircan O Candir N Kapucuoglu TA Serel M Ciris N Karahan, Urol Int 2006 77 107 113 10.1159/000093901 16888412
46. CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis. AG Abdou, APMIS 2007 115 1206 1218 10.1111/j.1600-0643.2007.00645.x 18092952
47. Non-invasive urothelial neoplasias. G Sauter F Algaba MB Amin C Busch J Cheville T Gasser D Grignon F Hofstaedter A Lopez-Beltran JI Epstein, WHO classification of non-invasive papillary urothelial tumors Lyon: IARC Press, Eble JN, Sauter G, Epstein JI, Sesterhenn I, 2004 89 157
48. LH Sobin C Wittekind, TNM Classification of Malignant Tumours New York: Wiley-Liss 2002
49. Molecular staging of bladder cancer. AP Mitra RH Datar RJ Cote, BJU Int 2005 96 7 12 10.1111/j.1464-410X.2005.05557.x 15963111
50. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. SF Shariat H Tokunaga J Zhou J Kim GE Ayala WF Benedict SP Lerner, J Clin Oncol 2004 22 1014 1024 10.1200/JCO.2004.03.118 14981102
51. Accumulation of nuclear p53 and tumor progression in bladder cancer. D Esrig D Elmajian S Groshen JA Freeman JP Stein SC Chen PW Nichols DG Skinner PA Jones RJ Cote, N Engl J Med 1994 331 1259 1264 10.1056/NEJM199411103311903 7935683
52. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. PK Lipponen, Int J Cancer 1993 53 365 370 10.1002/ijc.2910530304 8428790
53. A, B, H antigen expression in transitional cell carcinomas of the urinary bladder. BR Juhl SH Hartzen B Hainau, Cancer 1986 57 1768 1775 10.1002/1097-0142(19860501)57:9<1768::AID-CNCR2820570910>3.0.CO;2-E 2420436 (Pubitemid 16111986)
54. Estimation of ABO(H) isoantigen expression in bladder tumors. V Srinivas E Orihuela KO Lloyd LJ Old WF Whitmore Jr, J Urol 1985 133 25 28 3964875
55. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. AS Sarkis G Dalbagni C Cordon-Cardo ZF Zhang J Sheinfeld WR Fair HW Herr VE Reuter, J Natl Cancer Inst 1993 85 53 59 10.1093/jnci/85.1.53 7677935
56. Improved prognosis assessment for patients with bladder carcinoma. T Otto A Bex U Schmidt A Raz H Rübben, Am J Pathol 1997 150 1919 1923 9176385
57. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. V Toma D Hauri U Schmid D Ackermann R Maurer G Alund H Knönagel M Rist TC Gasser G Sauter J Roth, Am J Pathol 1999 155 1427 1432 10550296
58. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. JJ Del Pizzo A Borkowski SC Jacobs N Kyprianou, Am J Pathol 1999 155 1129 1136 10514396
59. Biomarkers for transitional cell carcinoma-con. M Schoenberg, Urology 2001 57 849 851 10.1016/S0090-4295(01)00975-X 11337280
60. Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. P Basset C Wolf N Rouyer JP Bellocq MC Rio P Chambon, Cancer 1994 74 1045 1049 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0. CO;2-7 7518738
61. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. A Talvensaari-Mattila P Pää kkö M Höyhtyä G Blanco-Sequeiros T Turpeenniemi-Hujanen, Cancer 1998 83 1153 1162 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID- CNCR14>3.0.CO;2-4 9740080
62. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. L Cheng RM Neumann A Nehra BE Spotts AL Weaver DG Bostwick, Cancer 2000 88 1663 1670 10.1002/(SICI)1097-0142(20000401)88: 7<1663::AID-CNCR21>3.0.CO;2-8 10738225
63. The natural history of bladder cancer: implications for therapy. R Lee MJ Droller, Urol Clin N Am 2000 27 1 13 10.1016/S0094-0143(05)70229-9
64. Natural history of urothelial dysplasia of the bladder. L Cheng JC Cheville RM Neumann DG Bostwick, Am J Surg Pathol 1999 23 443 447 10.1097/00000478-199904000-00009 10199474
65. Increased expression of the Bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. M Bai NJ Agnantis A Skyrlas E Tsanou S Kamina V Galani P Kanavaros, Mod Pathol 2003 16 471 480 10.1097/01.MP.0000067684.78221.6E 12748254 (Pubitemid 36618468)
66. Regulation of airway neurogenic inflammation by neutral endopeptidase. GU Di Maria S Bellofiore P Geppetti, Eur Respir J 1998 12 1454 1462 10.1183/09031936.98.12061454 9877509
67. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. J Ordi C Romagosa FA Tavassoli F Nogales A Palacin E Condom A Torne A Cardesa, Am J Surg Pathol 2003 27 178 186 10.1097/00000478-200302000- 00005 12548163
68. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. RI Cameron P Ashe DM O'Rourke H Foster WG McCluggage, Int J Gynecol Pathol 2003 22 272 276 10.1097/01.PGP.0000071044. 12278.43 12819395
69. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. AJ Cohen PA Bunn W Franklin C Magill-Solc C Hartmann B Helfrich L Gilman J Folkvord K Helm YE Miller, Cancer Res 1996 56 831 839 8631021
70. Expression of CD10 by stromal cells during colorectal tumor development. H Ogawa K Iwaya M Izumi M Kuroda H Serizawa Y Koyanagi K Mukai, Hum Pathol 2002 33 806 811 10.1053/hupa.2002.125773 12203213
71. Phenotypic expression of gastrointestinal differentiation markers in colorectal adenocarcinomas with liver metastasis. T Yao M Takata S Tustsumi K Nishiyama K Taguchi E Nagai M Tsuneyoshi, Pathology 2002 34 556 560 12555994
72. Tumor suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. J Dai R Shen M Sumitomo JS Goldberg Y Geng D Navarro S Xu JA Koutcher M Garzotto CT Powell DM Nanus, Clin Cancer Res 2001 7 1370 1377 11350908